Molecular targeted therapy in combination with chemotherapy for the treatment of platinum-resistant/refractory ovarian cancer (PROC): a systematic review and network meta-analysis - PubMed
9 hours ago
- #targeted-therapy
- #chemotherapy
- #ovarian-cancer
- Combining molecular targeted therapy with chemotherapy shows benefits for platinum-resistant/refractory ovarian cancer (PROC).
- Bevacizumab, sorafenib, and adavosertib combined with chemotherapy significantly improve overall survival (OS) and progression-free survival (PFS).
- Adavosertib + gemcitabine increases the risk of grade 3-4 adverse events (AEs), but these are manageable.
- Bevacizumab-based combinations, especially paclitaxel + bevacizumab, offer the best balance of efficacy and safety.
- Topotecan + sorafenib is an alternative for patients ineligible for anti-angiogenic therapy.